Respiratory Syncytial Virus Immunization Coverage Among Infants Through Receipt of Nirsevimab Monoclonal Antibody or Maternal Vaccination — United States, October 2023–March 2024
by from Morbidity and Mortality Weekly Report (MMWR) on (#6ZFKN)
This report describes an analysis of infants born from October 2023-March 2024 that had respiratory syncytial virus (RSV) immunization coverage through nirsevimab monoclonal antibodies or maternal vaccination.